Author

Lauren Highfield

Mass General Brigham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:protein sequence· 1

Frequent Co-Authors

Aaron N. HataiD· 2 shared Anna E. MaciagiD· 1 shared Beow Yong YeapiD· 1 shared Bin Wang· 1 shared Cathy ZhangiD· 1 shared Charlotte I. WangiD· 1 shared Daniel AndrussieriD· 1 shared Emily Hensley· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aaron N. HataORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 30, 2026

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition

Katherine Parker, Samar Ghorbanpoor, Wafa Malik…·Aaron N. Hata

This study shows that a dual inhibitor of KRASG12C in both ON and OFF states more effectively suppresses tumor growth than an OFF-specific inhibitor by reducing PI3K-AKT activation.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 23, 2026

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer

Takashi Sakai, Zofia Piotrowska, Charlotte I. Wang…·Ibiayi Dagogo‐Jack

The paper identifies MTAP loss in 18% of NSCLC specimens and shows PRMT5 inhibitors are effective in MTAP-deleted tumors, with enhanced activity when combined with TKIs.

DOI 10.64898/2026.01.21.700721

humanprotein sequence

𝕏 PostBluesky